Xenetic Biosciences announced that its abstract titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy" has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 1, 2026 in Chicago, Illinois.
The abstract details a DNase‑based therapeutic that degrades neutrophil extracellular traps (NETs) to improve the activity of CAR T‑cell therapies in solid tumors. By breaking down NETs, the approach aims to reduce tumor‑promoting inflammation and enhance CAR T‑cell infiltration and function, addressing a key barrier to the success of CAR T therapy in solid‑tumor settings.
Acceptance at ASCO provides Xenetic with a high‑profile platform to showcase its preclinical data, potentially attracting new partners or investors. The company is advancing its DNase program toward Phase 1 clinical trials for pancreatic carcinoma and other solid tumors, and maintains collaborations with The Scripps Research Institute, the University of Virginia, and PeriNess Ltd. The milestone reinforces Xenetic’s credibility and may open new partnership opportunities that could accelerate the clinical development of its DNase technology.
The market reaction to the announcement was mixed, with some investors expressing optimism about the scientific breakthrough while others remained cautious. Analysts have issued a consensus "Sell" rating, reflecting limited coverage and volatility in the company’s outlook.
Xenetic’s DNase platform seeks to improve outcomes of existing cancer treatments by targeting NETs, which are implicated in cancer progression, metastasis, and resistance to therapies. The abstract presentation is part of the company’s broader strategy to bring its DNase technology into clinical development and to enhance the efficacy of CAR T‑cell therapies in solid tumors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.